Schwarz UI et al. (2008) Genetic determinants of response to warfarin during initial anticoagulation. N Engl J Med 358: 999–1008
Patient responses to the anticoagulant warfarin are affected by polymorphisms in the genes that code for vitamin K epoxide reductase (VKORC1) and the enzyme cytochrome P4502C9 (CYP2C9); however, it is not known how these variants affect patients' sensitivity early during warfarin therapy. Schwarz et al. genotyped venous blood samples from a group of 297 patients receiving warfarin therapy and used physician-determined target therapeutic international normalized ratio (INR) ranges to assess early anticoagulation response according to CYP2C9 or VKORC1 genotype.
A greater number of individuals carrying predetermined VKORC1 variants had a first INR within the therapeutic range and a first INR of >4 (associated with increased risk of bleeding) within 28 days than did individuals without these variants (P = 0.02 and P = 0.04, respectively). VKORC1 haplotype also affected the percentage of time that an individual had INR values in excess of the therapeutic range (P = 0.03). CYP2C9 genotype only marginally affected time to first INR within the therapeutic range or the time spent above the INR therapeutic range, although carriers of the CYP2C9*2 or the CYP2C9*3 allele reached a first INR of >4 earlier than did those with the wild-type allele (P = 0.03). Both VKORC1 haplotype and, to a lesser degree, CYP2C9 genotype affected the average required warfarin dose during the first 2 weeks of therapy.
Variation in the VKORC1 haplotype affects the sensitivity of initial anticoagulation response to warfarin therapy; genotyping for this variation could help determine whether initial warfarin dose should be reduced to prevent overcoagulation during commencement of treatment.
Rights and permissions
About this article
Cite this article
Genetic determinants of variation in early response to warfarin. Nat Rev Cardiol 5, 356 (2008). https://doi.org/10.1038/ncpcardio1226
Issue Date:
DOI: https://doi.org/10.1038/ncpcardio1226